Beleave Inc. (“Beleave”) (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to announce that it will begin a clinical research program with Dr. Mohit Bhandari, to investigate the therapeutic use of cannabinoids for management of pain in musculoskeletal disorders. In North America, Europe, and Australia, chronic non-cancer pain is a large contributor to morbidity, affecting as much as 30% of the population. Musculoskeletal disorders can be triggering events that lead to the development of chronic pain in up to 40% of chronic pain cases. Options for pain management in musculoskeletal disorders, both surgical and non-surgical, remain limited.
Dr. Bhandari is a Professor and a Canada Research Chair at McMaster University, a University Scholar, and the Associate Chair of Research for Surgery. He is a world-leading researcher specializing in large international clinical trials in orthopaedic surgery, and is among the most cited and well published surgical researchers in the world. His research team has expertise in the full spectrum of health research methods including systematic reviews, meta-analyses, epidemiological studies, economic analyses and clinical trials. Dr. Bhandari has won numerous awards for contributions to research and evidence-based orthopaedics including the Order of Ontario, and the Kappa Delta award.
“Chronic pain associated with musculoskeletal disorders is common and devastating,” commented Beleave CEO, Roger Ferreira. “We are extremely happy to be partnering with Dr. Bhandari to investigate the therapeutic use of cannabinoids for management of pain in musculoskeletal disorder.”
Beleave Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“). Beleave’s wholly-owned subsidiary First Access Medical Inc. (“FAM“) has applied for a license to cultivate and sell medical cannabis pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and completed its pre-licensing inspection. Beleave’s purpose-built facility is located near Hamilton, Ontario.
This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the completion of the ACMPR licensing process, meeting the requirements of the ACMPR, and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.